Results Intervention with lutein-containing supplement significantly increased BCVA of both eyes (in within-group comparison), whereas placebo showed a similar effect on only the right-side eye without any effect on the left-side eye. For VRQOL, significant improvement was observed in lutein group but was not in placebo group (in within-group comparison).
Methods: Seventeen each subjects were allocated to placebo (placebo group) and lutein-containing supplement (lutein group). Lutein-containing supplement was taken orally for 6 weeks in a daily dose of 1320 mg (30 mg as lutein). Before the start and after the end of 6-week intervention, all subjects underwent determinations of best-spectacle corrected VA (BOVA) and examinations of VRQOL based on vision symptom VAS scores for efficacy evaluation.
Conclusions Lutein-containing supplement is considered to have beneficial effects on the elderly with complaint of depressed VRQOL.
Objectives: To study the potential of lutein-containing supplement to improve visual acuity (VA) and/or vision-related quality of life (VRQOL) in a randomized, double-blind, placebo-controlled trial with the healthy elderly aged 50 to 70 years who complained of subjective vision symptoms.
|Number of pages||10|
|Journal||Japanese Pharmacology and Therapeutics|
|Publication status||Published - 2014|
- Best-spectacle corrected visual acuity (BCVA)
- Intervention study
- Vision-related quality of life
- Visual function
ASJC Scopus subject areas
- Pharmacology (medical)